(firstQuint)Safety and Efficacy of PG102P for Uremic Pruritus in HD Patients.

 This is a multicenter, randomized, double-blind, placebo-controlled trial in which one group will be treated with PG102P (1.

5 g/day) and the other with a placebo.

 It is an investigator-initiated clinical trial.

 A superiority trial is planned to test the hypothesis that PG102P is effective in relieving pruritus for patients with ESRD undergoing HD.

.

 Safety and Efficacy of PG102P for Uremic Pruritus in HD Patients@highlight

In this study (SNUG trial), the investigators aim to investigate the anti-pruritic effect of PG102P in comparison with placebo in 80 patients undergoing HD.

